Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. Because it can cross the blood-brain barrier, MYMD-1 is also positioned to be a possible treatment for multiple sclerosis and other brain-related disorders. Chief Scientific Officer.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JUNE 1, 2021

Director of Medical Affairs and a Product Development Team lead at Greenwich Biosciences, where he played an important role in the complex, successful commercialization of the first cannabis-based product approved by the FDA to treat rare forms of epilepsy. CAMBRIDGE, Mass.–(BUSINESS Sesen Bio, Inc.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

MAY 19, 2022

FDA states it has received 104 reports of adverse events in patients who consumed delta-8 THC products between December 1, 2020 and February 28, 2022. The agency stated that it has received numerous adverse event reports involving delta-8 THC-containing products. CBD oil is an effective natural treatment for OCD.”. “If

THC 52

THC CBD Food Pets 52

Veriheal

OCTOBER 5, 2020

This bill also allows for dispensaries to “provide, disseminate, and publish educational and scientific material related to medical cannabis and its approved products and sponsor events about medical cannabis”. . Summary of Hawaiian Cannabis Regulations. Act 228 allows for the growth of cannabis for medical purposes. .

Edibles 52

Edibles Legalization Decriminalization Consumption 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 52

Therapy Research and Development Business Access 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

MAY 6, 2022

Examples of sellers’ language the FDA views as illegal are the following: “Our line of …CBD oil … is great for insomnia, epilepsy, MS, schizophrenia, and chronic pain.”. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Delta-8 is known to be successful in many cancer treatments.”.

THC 52

THC CBD Media Food 52

Cannabis Law Report

OCTOBER 26, 2021

MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 6, 2021

Preliminary in-vitro, ex-vivo, and in-vivo data demonstrated that AnQlar inhibits replication of SARS-CoV-2 and may inhibit viral spread as well as viral brain load at non-toxic concentrations. About Virpax Pharmaceuticals. For more information, please visit www.virpaxpharma.com. Forward-Looking Statement. Christopher M. Chipman, CPA.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Palliative care indications. Cancer pain.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

NOVEMBER 15, 2021

Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. VRP324 represents our first CNS disorder product indication. RECENT DEVELOPMENTS. Bruce and Michael F.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 8, 2021

Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. Christopher M.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

OCTOBER 26, 2019

The TGA does not evaluate any data relating to the trial. Data exclusivityThe TG Act provides a data exclusivity period of five years in relation to therapeutic goods containing a new active component (that is, an active substance that has not previously been a component of a product entered in the ARTG).

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Green Relief

MAY 13, 2018

It is the most commonly identified cause of epilepsy among adults. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. Preliminary data suggests that a synergistic combination of CBD and hypothermia may produce the best results. million Americans annually. CBD for CTE. Terpenes.

THC 64

THC CBD Cannabinoids Research and Development 64

Green Relief

MAY 12, 2018

It is the most commonly identified cause of epilepsy among adults. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. Preliminary data suggests that a synergistic combination of CBD and hypothermia may produce the best results. million Americans annually. CBD for CTE. Terpenes.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

The Cannigma

DECEMBER 22, 2021

Listen & Subscribe: Israel is world-renowned for the research and innovation that is taking place there, and unofficial data suggests that around 20% of the Israeli population uses cannabis. We have autism and epilepsy. Despite this, being in possession of a prescription is the only way that cannabis can be legally consumed.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Healer

JUNE 28, 2019

Average pain, worst pain and sleep disruption were measured daily during 5 weeks of treatment; other questionnaires measured quality of life and mood. Adverse events were dose-related and only the high-dose group compared unfavorably with placebo. A total of 360 patients were randomized; 263 completed. 006), mean worst pain (P =.011),

Cannabinoids 52

Cannabinoids THC Therapy Patients 52

Cannabis Law Report

OCTOBER 17, 2019

Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. Another researcher, New Frontier Data, pegged the global value of legal and illicit cannabis together at $340 billion in 2018.

Law 40

Law Seed-To-Sale Hemp Recreational 40